COVID-19 Outcomes in Solid Organ Transplant Recipients Who Received Tixagevimab-cilgavimab Prophylaxis and/or Bebtelovimab Treatment in a Nurse-driven Monoclonal Antibody Program During the Omicron SurgeWilla Cochran, Robin K. Avery, Sonsoles Salto‐Alejandre et al.|Transplantation|2022Cited by 25
Risk factors for unfavorable outcome and impact of early post-transplant infection in solid organ recipients with COVID-19: A prospective multicenter cohort studySonsoles Salto‐Alejandre, Maricela Valerio, Pilar Martín‐Dávila et al.|PLoS ONE|2021Cited by 22
Impact of Bebtelovimab Treatment Timing on COVID‐19 Outcomes in Ambulatory Solid Organ Transplant RecipientsSonsoles Salto‐Alejandre, Robin K. Avery, Willa Cochran et al.|Transplant Infectious Disease|2024Cited by 0